SHINGRIX subst sèche c solv (susp) flac 0.5 ml
7680679870017
CH-67987
J07BK03
08.08.
Reimbursement limitations:
0808 NEU
La prise en charge des coûts des vaccins au titre de mesure préventive dans le …
1 / 3
google
Details
- Product number
- 6798701
- CPT
- -
- Packaging group
- 1 + 1
- Unit
- Durchstechflasche(n)
- Composition
- Pulver: glycoproteini E viri Varicellae Zoster antigenum 50 µg, saccharum, polysorbatum 80, natrii dihydrogenophosphas dihydricus, dikalii phosphas anhydricus, pro praeparatione. Solvens: Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. Suspensio reconstituta: glycoproteini E viri Varicellae Zoster antigenum 50 µg, saccharum, polysorbatum 80, Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, natrii chloridum, natrii dihydrogenophosphas anhydricus, dikalii phosphas anhydricus, dinatrii phosphas, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.77 mg, kalium 0.18 mg.
Articles (1)
Shingrix, Pulver und Suspension zur Herstellung einer Injektionssuspension
Pulver
1 + 1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
PUL
|
50.0 UG | Substance | Wirkstoff (Principe actif) |
|
SOLV
|
- | Substance | HNIDK |
|
SUSR
|
50.0 UG | Substance | Wirkstoff (Principe actif) |
|
SOLV
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
PUL
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
PUL
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
PUL
|
- | Substance | HNIDK |
|
PUL
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SUSR
|
- | Substance | HNIDK |
|
SUSR
|
1.77 MG | Substance | HBESI |
|
SUSR
|
0.18 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 166.20
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/02/2022
Authorization holder
GlaxoSmithKline AG
6340 Baar
Authorization information
- Swissmedic authorization number
- 67987
- Drug name
- Shingrix, Pulver und Suspension zur Herstellung einer Injektionssuspension
- Galenic form
- PULVS
- ATC Code
- J07BK03
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 07/10/2021
- Authorization expiration date
- 06/10/2026
- IT number
- 08.08.
- Domain
- Human medicine
Packaging details
- Description (FR)
- SHINGRIX subst sèche c solv (susp) flac 0.5 ml
- Description (DE)
- SHINGRIX Trockensub c Solv (Susp) Durchstf 0.5 ml
- Market launch
- 07/10/2021
- Narcotic (BTM)
- No